Mankind Pharma board to review Q2 and H1 2025 financial results

Mankind Pharma Limited announced its board of directors will convene on Thursday, November 6, 2025. The primary agenda for this meeting is to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year period ending September 30, 2025. This intimation complies with SEBI regulations.

In a related development, the trading window for Mankind Pharma's securities, which closed on September 25, 2025, will remain shut until November 8, 2025. This closure is in accordance with SEBI regulations and the company's code of conduct for prevention of insider trading.

The official notice regarding these announcements has been uploaded to Mankind Pharma's website, www.mankindpharma.com, for public record and stakeholder information. The announcement was signed by Hitesh Kumar Jain, company secretary and compliance officer, on October 27, 2025.